ASTRAZENECA STOPS GALIDA TRIAL

AstraZeneca is canceling its late-stage clinical trials of its Galida drug for Type 2 diabetes after tests showed it was not more effective than currently available treatments.

Clinical tests showed that some patients taking Galida in clinical trials around the world developed elevated serum creatinine levels, which could be associated with kidney damage, and an associated decrease in kidney filtering function. However, the drug poses no immediate safety risk for the 2,245 patients worldwide receiving it.